Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.ajantapharma.com | |
Market Cap | 15,217.42 Cr. | |
Enterprise Value(EV) | 14,885.34 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 48.15 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 24.67 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.80 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 291.74 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 4.07 | Calculated using Price: 1,187.70 |
Dividend Yield | 0.53 | Period Ending 2022-03 |
No. of Shares Subscribed | 12.81 Cr. | 128,125,155 Shares |
FaceValue | 2 | |
Company Profile | ||
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Emerging markets are the major contributors in company's branded generic business where it is present across Asia and Africa. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. |
1 Day |
|
+2.03% |
1 Week |
|
-1.71% |
1 Month |
|
-0.01% |
3 Month |
|
-4.71% |
6 Month |
|
-7.12% |
1 Year |
|
-16.02% |
2 Year |
|
-1.77% |
5 Year |
|
+33.92% |
10 Year |
|
+1063.16% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 47.47 | 43.24 | 40.93 | 36.77 | 26.00 | 18.07 | 19.32 | 23.38 | 22.77 | |
Return on Capital Employed (%) | 54.52 | 56.43 | 51.59 | 45.72 | 34.49 | 23.84 | 27.44 | 32.20 | 29.37 | |
Return on Assets (%) | 28.05 | 29.57 | 31.66 | 30.69 | 22.06 | 14.52 | 14.44 | 17.03 | 16.79 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 593 | 841 | 1,191 | 1,568 | 2,041 | 2,245 | 2,599 | 2,996 | 3,264 | 3,603 | |
Non Curr. Liab. | 81 | 56 | 29 | 9 | 39 | 162 | 228 | 275 | 279 | 65 | |
Curr. Liab. | 275 | 250 | 260 | 247 | 346 | 498 | 746 | 839 | 838 | 705 | |
Minority Int. | |||||||||||
Equity & Liab. | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,906 | 3,572 | 4,109 | 4,381 | 4,373 | |
Non Curr. Assets | 429 | 513 | 716 | 973 | 1,202 | 1,605 | 1,791 | 1,891 | 1,926 | 1,725 | |
Curr. Assets | 520 | 633 | 763 | 851 | 1,224 | 1,301 | 1,781 | 2,218 | 2,455 | 2,649 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,906 | 3,572 | 4,109 | 4,381 | 4,373 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 1,208 | 1,474 | 1,734 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,731 | |
Other Income | 14 | 17 | 21 | 24 | 24 | 21 | 92 | 26 | 116 | 138 | |
Total Income | 1,222 | 1,490 | 1,755 | 2,007 | 2,150 | 2,076 | 2,680 | 2,916 | 3,457 | 3,869 | |
Total Expenditure | -840 | -968 | -1,147 | -1,296 | -1,467 | -1,489 | -1,905 | -1,891 | -2,412 | -2,937 | |
PBIDT | 382 | 522 | 608 | 711 | 683 | 588 | 776 | 1,025 | 1,045 | 932 | |
Interest | -9 | -6 | -5 | -1 | 0 | -1 | -12 | -8 | -10 | -12 | |
Depreciation | -44 | -52 | -44 | -61 | -60 | -72 | -96 | -116 | -125 | -129 | |
Taxation | -96 | -146 | -143 | -141 | -154 | -127 | -196 | -246 | -197 | -174 | |
Exceptional Items | -8 | -4 | |||||||||
PAT | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 617 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 617 | |
Adjusted EPS | 18 | 23 | 31 | 38 | 36 | 30 | 36 | 50 | 56 | 48 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 234 | 212 | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | |
Cash Fr. Inv. | -104 | -188 | -158 | -209 | -383 | -256 | -223 | -224 | -282 | -74 | |
Cash Fr. Finan. | -104 | -20 | -105 | -117 | -202 | 0 | -147 | -129 | -318 | -460 | |
Net Change | 26 | 4 | 16 | 0 | 24 | 25 | 4 | 104 | -24 | 28 | |
Cash & Cash Eqvt | 34 | 39 | 54 | 41 | 66 | 91 | 95 | 199 | 178 | 205 |
Tue, 07 Feb 2023
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot Further to our letter dated 1st February 2023 please find enclosed herewith Postal Ballot Notice together with the Explanatory Statement seeking approval of members of the Company for reappointment and remuneration of Mr. Yogesh Agrawal as the Managing Director and Mr. RajeshAgrawal as the Joint Managing Director.The Postal Ballot notice has been sent by e-mail on 7th February 2023 to the members who have registered their e-mail IDs with Depository Participant(s) or with the Company. E-voting period will commence from Wednesday 8th February 2023 IST at 9.00 a.m. and will end on Thursday 9th March 2023 IST at 5.00 p.m. |
Thu, 02 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 audio call recording of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Companys website and can be accessed through the link https://ajantapharma.com//images/EarningsCallAudioQ3(Oct-Dec)2022-23.mp3 |
Thu, 02 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 47 of the Listing Regulations please find enclosed copies of financial results of the Company for the quarter and nine months ended 31st December 2022 published in the following newspapers on 2nd February 2023:1. Mumbai edition of Economic Times and2. Mumbai edition of Maharashtra Times. |
Tue, 07 Feb 2023 |
|
|
|
|
|